New Phase 3 Data on PD-L1 Vs. Chemotherapy for First-Line NSCLC
Dr. Farzanna Haffizulla interviews Gilberto de Lima Lopes Jr., MD, MBA, FAMS on New Phase 3 Data on PD-L1 Vs. Chemotherapy for First-Line NSCLC
Video originally published on PracticeUpdate.com on 06/06/2018 -- https://www.practiceupdate.com/content/asco-2018-new-phase-3-data-on-pd-l1-vs-chemotherapy-for-first-line-nsclc/69060/45/1/3
--
Follow PracticeUpdate:
Twitter: https://twitter.com/practiceupdate
Facebook: https://www.facebook.com/practiceupdate
Instagram: https://www.instagram.com/practiceupdate_elsevier
LinkedIn: https://www.linkedin.com/showcase/practiceupdate
Register for PracticeUpdate for free at https://www.practiceupdate.com/welcome
Видео New Phase 3 Data on PD-L1 Vs. Chemotherapy for First-Line NSCLC канала PracticeUpdate
Video originally published on PracticeUpdate.com on 06/06/2018 -- https://www.practiceupdate.com/content/asco-2018-new-phase-3-data-on-pd-l1-vs-chemotherapy-for-first-line-nsclc/69060/45/1/3
--
Follow PracticeUpdate:
Twitter: https://twitter.com/practiceupdate
Facebook: https://www.facebook.com/practiceupdate
Instagram: https://www.instagram.com/practiceupdate_elsevier
LinkedIn: https://www.linkedin.com/showcase/practiceupdate
Register for PracticeUpdate for free at https://www.practiceupdate.com/welcome
Видео New Phase 3 Data on PD-L1 Vs. Chemotherapy for First-Line NSCLC канала PracticeUpdate
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![The Immune Landscape of Residual TNBC After Neoadjuvant Chemotherapy](https://i.ytimg.com/vi/duwrC0exsoc/default.jpg)
![Heroin/Opioid Addiction Among Cancer Patients – Recommendations for Patients](https://i.ytimg.com/vi/O7D2oYwy15Q/default.jpg)
![Cancer Related Anemia](https://i.ytimg.com/vi/3_Hx39-CFmM/default.jpg)
![A Review of Immunotherapy and Targeted Therapy in Glioblastoma](https://i.ytimg.com/vi/Y5O-5-VyxmU/default.jpg)
![New Concepts in Metastatic Prostate Cancer](https://i.ytimg.com/vi/SHyOIoX-A88/default.jpg)
![Salvage vs Adjuvant Therapy in High-Risk Prostate Cancer](https://i.ytimg.com/vi/RjvR0JdcRJ0/default.jpg)
![Erlotinib Plus Ramucirumab for EGFR Mutant Lung Cancer](https://i.ytimg.com/vi/1x28xsWW47Y/default.jpg)
![Practice Implications of Real World Data on First-Line Pazopanib in mRCC](https://i.ytimg.com/vi/uJLqyL0tUFs/default.jpg)
![Metastatic Breast Cancer: Triple Negative](https://i.ytimg.com/vi/zemQ7V6VTs8/default.jpg)
![PCI versus medical therapy for patients with symptomatic coronary artery disease?](https://i.ytimg.com/vi/PibUJpVbkRE/default.jpg)
![Interview on Multiple Myeloma Trials](https://i.ytimg.com/vi/yFqhhy4ijXY/default.jpg)
![Gene Therapy for Advanced Parkinson’s Disease](https://i.ytimg.com/vi/2xRNGCJ2Kz0/default.jpg)
![New Data on Pancreatic Cancer from ASCO GI](https://i.ytimg.com/vi/RhhVRL1KRzg/default.jpg)
![Schizophrenia: Acute vs Chronic Management](https://i.ytimg.com/vi/BcP8Dnu4flc/default.jpg)
![Adjuvant T-DM1 for Stage I HER2+ Breast Cancer](https://i.ytimg.com/vi/2a9e5YHF76M/default.jpg)
![Depression Management: First-Line Treatments](https://i.ytimg.com/vi/AlQ6a7EiQCk/default.jpg)
![JAK2 and PD-L1 in 9p24 Amplified Breast Cancer](https://i.ytimg.com/vi/ePZyTMu5GPI/default.jpg)
![ADA 2018: Observations from the DEVOTE trial](https://i.ytimg.com/vi/Aw5rLsT9pUw/default.jpg)
![Immunotherapy in the Management of Metastatic Triple Negative Breast Cancer](https://i.ytimg.com/vi/gsRzi-HaUDs/default.jpg)
![Mitoxantrone and Veliparib in Prostate Cancer: Updates from ASCO 2017](https://i.ytimg.com/vi/ErTQf5RpM60/default.jpg)
![Use of Colony-Stimulating Factors Among Patients Receiving Intermediate-Risk Chemotherapies](https://i.ytimg.com/vi/EwioLFBRFoM/default.jpg)